Three Case of Three Extremes of Autoimmune Hepatitis from Bangladesh and Review of Literature

Sheikh Mohammad Noor E Alam¹, Md Abdur Rahim², Rokshana Begum³, Ahmed Lutful Moben⁴, Bishnu Pada Dey⁵, Sheikh Mohammad Fazle Akbar⁶ and Mamun Al Mahtab⁷*

¹Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh
²Department of Hepatology, International Medical College, Gazipur, Bangladesh
³Department of Hepatology, Shaheed Suhrawardy Medical College, Dhaka, Bangladesh
⁴Department of Hepatology, Kurmitola General Hospital, Dhaka, Bangladesh
⁵Department of Pathology, Bangladesh Medical University, Dhaka, Bangladesh
⁶Ehime University, Ehime, Japan, Oita University, Oita, Japan and Miyakawa Memorial Research Foundation, Tokyo, Japan
⁷Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh

*Corresponding Author: Mamun Al Mahtab, Professor, Department of Hepatology, Bangladesh Medical University, Dhaka, Bangladesh.

Received: July 21, 2025; Published: September 08, 2025

Abstract

Autoimmune hepatitis is a rare chronic liver disease of genetic predisposition, which is triggered by environmental factors. Although autoimmune hepatitis affects all ages and genders across the world, it is often encountered in white females in their twenties, sixties or seventies. Like diagnosis, treatment of autoimmune hepatitis remains challenging and often demands long-term, tailored specialist attention. In specialist Hepatology practice, one must remain vigilant to pick up autoimmune hepatitis early and manage appropriately, as without which the disease is associated with frustrating prognosis.

 Keywords: Autoimmune Hepatitis; Liver Cirrhosis; Bangladesh

References

1. European Association for the Study of the Liver. “EASL Clinical Practice Guidelines: Autoimmune hepatitis”. Journal of Hepatology 63 (2015): 971-1004.
2. Mieli-Vergani G., et al. “Autoimmune hepatitis”. Nature Reviews Disease Primers 4 (2018): 18017.
3. Mack CL., et al. “Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases”. Hepatology 72 (2020): 671-722.
4. Lv T., et al. “Systematic review and meta-analysis on the incidence and prevalence of autoimmune hepatitis in Asian, European, and American population”. Journal of Gastroenterology and Hepatology 34 (2019): 1676-1684.
5. Liwinski T., et al. “The intestinal and biliary microbiome in autoimmune liver disease-current evidence and concepts”. Seminar on Immunopathology 44 (2022): 485-507.
6. van Gerven NMF., et al. “HLA-DRB1*03:01 and HLA-DRB1*04:01 modify the presentation and outcome in autoimmune hepatitis type-1”. Genes Immune 16 (2015): 247-252.
7. Zachou K., et al. “Impact of genetic and environmental factors on autoimmune hepatitis”. Journal of Translational Autoimmunity 4 (2021): 100125.
8. Muratori L and Longhi MS. “The interplay between regulatory and effector T cells in autoimmune hepatitis: Implications for innovative treatment strategies”. Journal of Autoimmunity 46 (2013): 74-80.
9. Vuerich M., et al. “Dysfunctional Immune Regulation in Autoimmune Hepatitis: From Pathogenesis to Novel Therapies”. Frontiers in Immunology 12 (2021): 746436.
10. Longhi MS., et al. “Regulatory T cells in autoimmune hepatitis: an updated overview”. Journal of Autoimmunity 119 (2021): 102619.
11. Ferri S., et al. “HCV and autoimmunity”. Current Pharmaceutical Design 14 (2008): 1678-1685.
12. Berry PA and Smith-Laing G. “Hepatitis A vaccine associated with autoimmune hepatitis”. World Journal of Gastroenterology 13 (2007): 2238-2289.
13. Perumalswami P., et al. “Vaccination as a triggering event for autoimmune hepatitis”. Seminar on Liver Disease 29 (2009): 331-334.
14. Sasaki T., et al. “Autoimmune hepatitis following influenza virus vaccination: Two case reports”. Medicine (Baltimore) 97 (2018): e11621.
15. Muratori P., et al. “Development of autoimmune hepatitis after influenza vaccination; trigger or killer?” Clinics and Research in Hepatology and Gastroenterology 43 (2019): e95-96.
16. McShane C., et al. “The mRNA COVID-19 vaccine - A rare trigger of autoimmune hepatitis?”. Journal of Hepatology 75 (2021): 1252-1254.
17. Londono MC., et al. “Another case of autoimmune hepatitis after SARS-CoV-2 vaccination - still casualty?” Journal of Hepatology 75 (2021): 1248-1249.
18. Zin Tun GS., et al. “Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed”. Journal of Hepatology 76 (2022): 747-749.
19. Suzuki Y., et al. “Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population-based epidemiological study”. Hepatology 75 (2022): 759-760.
20. Ferronato M., et al. “Liver injury with autoimmune features after vaccination against SARS-CoV-2: The verdict is still open”. European Journal of Internal Medicine (2022).
21. Wei Y., et al. “Alterations of gut microbiome in autoimmune hepatitis”. Gut 69 (2020): 569-577.
22. Lou J., et al. “Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals”. Frontiers in Cellular and Infection Microbiology 10 (2020): 342.
23. Elsherbiny NM., et al. “Autoimmune Hepatitis: Shifts in Gut Microbiota and Metabolic Pathways among Egyptian Patients”. Microorganisms 8 (2020): E1011.
24. Liwinski T., et al. “A disease-specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis”. Aliment Pharmacology Therapy 51 (2020): 1417-1428.
25. Rao B., et al. “Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis”. Frontiers in Cellular and Infection Microbiology 11 (2021): 656674.
26. Muratori L., et al. “Diagnosis and management of autoimmune hepatitis”. BMJ 380 (2023): e070201.
27. Di Giorgio A., et al. “Fulminant hepatic failure of autoimmune aetiology in children”. Journal of Pediatric Gastroenterology and Nutrition 60 (2015): 159-164.
28. Aljumah AA., et al. “Acute onset autoimmune hepatitis: Clinical presentation and treatment outcomes”. Annals of Hepatology 18 (2019): 439-444.
29. Muratori P., et al. “Clinical and prognostic implications of acute onset of Autoimmune Hepatitis: An Italian multicentre study”. Digestive and Liver Disease 50 (2018): 698-702.
30. Ferrari R., et al. “Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the‘ acute’ type”. QJM 97 (2004): 407-412.
31. Joshita S., et al. “Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey”. Journal of Gastroenterology 53 (2018): 1079-1088.
32. Porta G., et al. “Autoimmune hepatitis in 828 Brazilian children and adolescents: clinical and laboratory findings, histological profile, treatments, and outcomes.” Journal of Pediatrics (Rio J) 95 (2019): 419-427.
33. Rahim MN., et al. “Approach to the patient with acute severe autoimmune hepatitis”. JHEP Report 2 (2020): 100149.
34. Rahim MN., et al. “Acute Severe Autoimmune Hepatitis: Corticosteroids or Liver Transplantation?” Liver Transplantation 25 (2019): 946-959.
35. Yeoman AD., et al. “Prognosis of acute severe autoimmune hepatitis (AS-AIH): the role of corticosteroids in modifying outcome”. Journal of Hepatology 61 (2014): 876-882.
36. Muratori P., et al. “Features and Progression of Asymptomatic Autoimmune Hepatitis in Italy”. Clinical Gastroenterology and Hepatology 14 (2016): 139-146.
37. Gronbaek L., et al. “Extrahepatic autoimmune diseases in patients with autoimmune hepatitis and their relatives: A Danish nationwide cohort study”. Liver International 39 (2019): 205-214.
38. Muratori P., et al. “Autoimmune liver disease and concomitant extrahepatic autoimmune disease”. European Journal of Gastroenterology and Hepatology 27 (2015): 1175-1179.
39. Wong GW and Heneghan MA. “Association of Extrahepatic Manifestations with Autoimmune Hepatitis”. Digestive Diseases 33 (2015): 25-35.
40. Muhling T., et al. “Overlap of concurrent extrahepatic autoimmune diseases is associated with milder disease severity of newly diagnosed autoimmune hepatitis”. Hepatobiliary and Pancreatic Diseases International 20 (2021): 21-27.
41. Paolella G., et al. “Pediatric autoimmune liver disease and extra-hepatic immune-mediated comorbidities”. Digestive and Liver Disease 51 (2019): 281-285.
42. Arndtz K., et al. “Multiparametric Magnetic Resonance Imaging, Autoimmune Hepatitis, and Prediction of Disease Activity”. Hepatology Communications 5 (2021): 1009-1020.
43. de Boer YS., et al. “Assessment of the histopathological key features in autoimmune hepatitis”. Histopathology 66 (2015): 351-362.
44. Hennes EM., et al. “International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis”. Hepatology 48 (2008): 169-176.
45. Czaja AJ. “Performance parameters of the diagnostic scoring systems for autoimmune hepatitis”. Hepatology 48 (2008): 1540-1548.
46. Neuhauser M., et al. “Autoimmune hepatitis-PBC overlap syndrome: a simplified scoring system may assist in the diagnosis”. American Journal of Gastroenterology 105 (2010): 345-353.
47. Muratori P., et al. “Type 1 and type 2 autoimmune hepatitis in adults share the same clinical phenotype”. Aliment Pharmacology and Therapy 41 (2015): 1281-1287.
48. Roepe IG., et al. “Presentation and Outcomes of Autoimmune Hepatitis Type 1 and Type 2 in Children: A Single-center Study”. Journal of Pediatric Gastroenterology and Nutrition 72 (2021): 101-107.
49. Trivedi PJ and Hirschfield GM. “Recent advances in clinical practice: epidemiology of autoimmune liver diseases”. Gut 70 (2021): 1989-2003.
50. Muratori P., et al. “Autoimmune hepatitis in Italy: the Bologna experience”. Journal of Hepatology 50 (2009): 1210-1218.
51. Hartl J., et al. “Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis”. Journal of Hepatology 65 (2016): 769-775.
52. Peiseler M., et al. “Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis”. Clinical Gastroenterology and Hepatology 16 (2018): 260-267.e1.
53. Woynarowski M., et al. “Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents”. Journal of Pediatrics 163 (2013): 1347-53.e1.
54. Johnson PJ., et al. “Azathioprine for long-term maintenance of remission in autoimmune hepatitis”. The New England Journal of Medicine 333 (1995): 958-963.
55. Lamers MMH., et al. “Treatment options for autoimmune hepatitis: a systematic review of randomized controlle trials”. Journal of Hepatology 53 (2010): 191-198.
56. Lohse AW., et al. “Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group”. Journal of Hepatology 73 (2020): 1496-506.
57. Hubener S., et al. “Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance”. Clinical Gastroenterology and Hepatology 14 (2016): 445-453.
58. Hennes EM., et al. “Mycophenolate mofetil as second line therapy in autoimmune hepatitis?” American Journal of Gastroenterology 103 (2008): 3063-3070.
59. Tarao K., et al. “Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment”. Cancer Medicine 8 (2019): 1054-1065.
60. Yeoman AD., et al. “Evaluation of risk factors in the development of hepatocellular carcinoma in autoimmune hepatitis: Implications for follow-up and screening”. Hepatology 48 (2008): 863-870.
61. Park SZ., et al. “Hepatocellular carcinoma in autoimmune hepatitis”. Digestive Diseases and Sciences 45 (2000): 1944-1948.
62. Mahtab MA., et al. “Two Extremes of Autoimmune Hepatitis: Report of Two Cases from Bangladesh”. Hungarian Medical Journal2 (2008): 257-260.
63. Benzamin M., et al. “Autoimmiune Hepatitis in Children: Two Case Report”. Bangladesh Medical Journal1 (2021): 45-50.

Citation

Citation: Mamun Al Mahtab., et al. “Three Case of Three Extremes of Autoimmune Hepatitis from Bangladesh and Review of Literature”.Acta Scientific Medical Sciences 9.10 (2025): 16-25.

Copyright

Copyright: © 2025 Mamun Al Mahtab., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.